Press release
Chronic Myeloid Leukemia Pipeline: Driving Innovation with 25+ Pioneering Companies Advancing Groundbreaking Therapies
Chronic Myeloid Leukemia Pipeline
DelveInsight's "Chronic Myelocytic Leukemia Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Chronic Myelocytic Leukemia market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.
For emerging Chronic Myelocytic Leukemia drugs, the Chronic Myelocytic Leukemia pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Chronic Myelocytic Leukemia Pipeline Report
• DelveInsight's Chronic Myelocytic Leukemia Pipeline analysis depicts a robust space with 25+ active players working to develop 25+ pipeline drugs for Chronic Myelocytic Leukemia treatment.
• The leading Chronic Myelocytic Leukemia companies include Novartis Oncology, Servier, Eltrombopag, Immune-Onc Therapeutics, H3 Biomedicine, Chroma Therapeutics, Nerviano Medical Sciences, Astex Pharmaceuticals, Takeda Oncology, Argenx, Kura Oncology, Incyte Corporation, Genentech, Inc., Sensei Biotherapeutics, Pfizer, BioLite, Inc., Newave Pharmaceutical Inc., Ellipses Pharma, Eli Lilly and Company, Aprea Therapeutics, Treadwell Therapeutics, Prelude Therapeutics, Onconova Therapeutics, Immune Pharmaceuticals, Teva Pharmaceutical Industries, and others are evaluating their lead assets to improve the Chronic Myelocytic Leukemia treatment landscape.
• Key Chronic Myelocytic Leukemia pipeline therapies in various stages of development include Imatinib, Radotinib, Olverembatinib, Venetoclax, Sabatolimab, Enasidenib, and others.
• In January 2025, Handa Pharmaceuticals announced that its U.S. subsidiary, Handa Therapeutics, acquired PHYRAGO (dasatinib) tablets, an FDA-approved treatment for chronic myeloid leukemia developed by Nanocopoeia. PHYRAGOTM is the first dasatinib product that can be co-administered with gastric acid-reducing agents.
• In November 2024, the FDA approved a reformulated version of nilotinib (Danziten) for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in the chronic phase, and for those with chronic or acute-phase disease resistant or intolerant to prior imatinib treatment.
• In October 2024, Novartis announced that the FDA granted accelerated approval for SCEMBLIX (asciminib) for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP).
Request a sample and discover the recent breakthroughs happening in the Chronic Myelocytic Leukemia pipeline landscape @ https://www.delveinsight.com/report-store/chronic-myelocytic-leukemia-cml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Chronic Myelocytic Leukemia Overview
Chronic Myelomonocytic Leukemia (CMML) is a rare type of leukemia characterized by an elevated number of monocytes in the blood and bone marrow. Although it includes "leukemia" in its name, the World Health Organization (WHO) classifies CMML as a mixed myelodysplastic/myeloproliferative neoplasm (MDS/MPN). This classification reflects the disease's dual characteristics-features of myelodysplastic syndromes (MDS), which impact normal blood cell production, and myeloproliferative neoplasms (MPN), where bone marrow stem cells produce excessive blood cells, including red cells, white cells, or platelets.
Find out more about Chronic Myelocytic Leukemia medication @ https://www.delveinsight.com/report-store/chronic-myelocytic-leukemia-cml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Chronic Myelocytic Leukemia Treatment Analysis: Drug Profile
Sabatolimab: Novartis Oncology
Sabatolimab (MBG 453) is a monoclonal antibody targeting T-cell immunoglobulin and mucin domain 3 (TIM-3), under development by Novartis Oncology. It is currently in Phase III clinical trials for the treatment of Chronic Myeloid Leukemia (CML).
Enasidenib: Servier
Enasidenib (AG 221) is an orally administered small molecule inhibitor of isocitrate dehydrogenase 2 (IDH2), developed by Servier. The drug is presently in Phase I clinical trials for the treatment of Chronic Myeloid Leukemia (CML).
Key Chronic Myelocytic Leukemia Therapies and Companies
• Imatinib: Novartis Pharmaceuticals
• Radotinib HCl: Il-Yang Pharm. Co., Ltd.
• Olverembatinib: Ascentage Pharma Group Inc.
• Venetoclax: AbbVie
• Sabatolimab: Novarits Oncology
• Enasidenib: Servier
Learn more about the novel and emerging Chronic Myelocytic Leukemia pipeline therapies @ https://www.delveinsight.com/report-store/chronic-myelocytic-leukemia-cml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Chronic Myelocytic Leukemia Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Scope of the Chronic Myelocytic Leukemia Pipeline Report
• Coverage: Global
• Key Chronic Myelocytic Leukemia Companies: Novartis Oncology, Servier, Eltrombopag, Immune-Onc Therapeutics, H3 Biomedicine, Chroma Therapeutics, Nerviano Medical Sciences, Astex Pharmaceuticals, Takeda Oncology, Argenx, Kura Oncology, Incyte Corporation, Genentech, Inc., Sensei Biotherapeutics, Pfizer, BioLite, Inc., Newave Pharmaceutical Inc., Ellipses Pharma, Eli Lilly and Company, Aprea Therapeutics, Treadwell Therapeutics, Prelude Therapeutics, Onconova Therapeutics, Immune Pharmaceuticals, Teva Pharmaceutical Industries, and others.
• Key Chronic Myelocytic Leukemia Pipeline Therapies: Imatinib, Radotinib, Olverembatinib, Venetoclax, Sabatolimab, Enasidenib, and others.
Dive deep into rich insights for drugs used for Chronic Myelocytic Leukemia treatment; visit @ https://www.delveinsight.com/report-store/chronic-myelocytic-leukemia-cml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Chronic Myelocytic Leukemia Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Chronic Myelocytic Leukemia Pipeline Therapeutics
6. Chronic Myelocytic Leukemia Pipeline: Late-Stage Products (Phase III)
7. Chronic Myelocytic Leukemia Pipeline: Late-Stage Products (Phase III)
8. Chronic Myelocytic Leukemia Pipeline: Mid-Stage Products (Phase II)
9. Chronic Myelocytic Leukemia Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Myeloid Leukemia Pipeline: Driving Innovation with 25+ Pioneering Companies Advancing Groundbreaking Therapies here
News-ID: 3936870 • Views: …
More Releases from DelveInsight
Atherosclerosis Pipeline: 15+ Trailblazing Companies Driving the Future of Innov …
The atherosclerosis market is experiencing a wave of therapeutic innovation, driven by key players such as Novo Nordisk, Amgen, Merck Sharp & Dohme, Afimmune, Silence Therapeutics, and Verve Therapeutics. With a focus on targeted lipid-lowering therapies, gene editing solutions, and novel anti-inflammatory agents, these companies are advancing precision medicine approaches to tackle the root causes of plaque buildup and cardiovascular risk. From PCSK9 inhibitors to RNA-based drugs and CRISPR-driven therapies,…
Malaria Pipeline: 15+ Pioneering Companies Advancing the Next Wave of Innovative …
The malaria therapeutics and vaccine market is undergoing a critical transformation, led by innovators such as Sanaria, GlaxoSmithKline, Novartis, Bharat Biotech, and GeoVax. With the emergence of genetically attenuated sporozoite vaccines, transmission-blocking candidates, and novel antimalarial compounds, these companies are redefining prevention and treatment paradigms. The pipeline is especially focused on overcoming drug resistance and improving efficacy in endemic regions, with new-age platforms offering hope for long-term malaria control and…
Hypercholesterolemia Pipeline: 25+ Leading Innovators Driving the Future of Chol …
The hypercholesterolemia market is being reshaped by biologics, RNA-based therapies, and gene-editing tools developed by industry leaders such as Amgen, Novartis, Verve Therapeutics, Arrowhead Pharmaceuticals, and LIB Therapeutics. With innovations like PCSK9 inhibitors, ANGPTL3 silencers, and CRISPR-based precision therapies, companies are offering more durable lipid-lowering solutions beyond statins. These advancements are setting the stage for personalized cholesterol management, particularly in patients who are genetically predisposed or intolerant to statins.
DelveInsight's "Hypercholesterolemia…
T-Cell Lymphoma Pipeline: 90+ Leading Companies Transforming the Landscape of Ta …
The T-cell lymphoma market is rapidly evolving with targeted therapies and immuno-oncology agents spearheaded by companies like Astex Pharmaceuticals, Corvus Pharmaceuticals, ViGenCell Inc., Affimed GmbH, and MediSix Therapeutics. With increasing focus on antibody-drug conjugates, bispecific antibodies, and CAR-T cell therapies, these players are addressing unmet needs across subtypes such as PTCL and CTCL. The innovation surge is aimed at improving survival outcomes in relapsed or refractory settings, where traditional chemotherapies…
More Releases for Chronic
Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Reviewed, …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H1, 2017”, provides an overview of Chronic Kidney Disease (Chronic Renal Failure) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Kidney Disease (Chronic Renal Failure). Report includes an overview of trial numbers and…
Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Market Res …
Latest industry research report on: Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts
GlobalData's clinical trial report, Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H1, 2017" provides an overview of Chronic Kidney Disease (Chronic Renal Failure) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Kidney…
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, T …
Orbisreserach.Com Adds “H1 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Market Pipeline Review 2017 Trend Analysis Report Report” To Its Research Database
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2017, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline landscape.
Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the…
Boot chronic pain
For immediate release
Due to our rushed lives and stressful environment, many people are suffering from chronic pain and fatigue.
We feel permanently tired and are barely able to get through our normal day. One is able to change this status when following the guidelines the book "Tired of being Tired to the point of being Gatvol (Fed Up). Some people will need a team of medical practitioners to help them…
Global Chronic, Acute, And Neuropathic Pain Market: Opioids To Remain Most Value …
The research report, titled “Frontier Pharma: Chronic, Acute And Neuropathic Pain - GPCR And Nerve Growth Factor-Based Therapies Offer Strong Potential In Difficult-To-Treat Subtypes,” analyzes the historical as well as the existing performance of this market, emphasizing specifically on various types of therapies applied to treat chronic, acute, and neuropathic pain.
According to this 68-page study, the worldwide market for chronic, acute, and neuropathic pain has been observing a significant…
Targeting chronic pain
With the support of the Austrian Science Fund FWF, the neurophysiologist Ruth Drdla-Schutting is investigating the role astrocytes play in the genesis of chronic pain. With the help of innovative gene technology (DREADDs), scientists are tailoring treatment specifically to these cells that are the most numerous found in the central nervous system.
Pain is an important protection system of the human body. But when it becomes chronic, as it frequently…
